noom.glp 1 Noom Med Plans & Pricing Noom GLP-1 Access and Transparency
Description
Yazbeck et al
The RACGP has been calling for effective obesity-management medication to be subsidised on the Pharmaceutical Benefits Scheme (PBS) to reduce health inequity and remove the cost barrier for many Australians
Now considered a landmark in the GLP-1 field, the article listed Mojsov as the first author and Habener as the last, a position customarily reserved for the senior author (Couzin-Frankel 8 Sept 2023
This pricing model appeals to uninsured patients, those with high-deductible plans, and individuals whose insurance denies coverage
It beat AstraZenecas Farxiga and is on track for 2026 approval
